HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

betibeglogene autotemcel

Also Known As:

LTF-303; autologous CD34+ cells encoding beta A-T87Q-globin gene; zynteglo

Networked: 9 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - betibeglogene autotemcel: 9

Experts

1.	Anurathapan, Usanarat: 2 articles (01/2022 - 01/2021)
2.	Asmal, Mohammed: 2 articles (01/2022 - 01/2021)
3.	Hongeng, Suradej: 2 articles (01/2022 - 01/2021)
4.	Algeri, Mattia: 1 article (01/2022)
5.	Amrolia, Persis J: 1 article (01/2022)
6.	Carpenter, Ben: 1 article (01/2022)
7.	Chabannon, Christian: 1 article (01/2022)
8.	Colvin, Richard A: 1 article (01/2022)
9.	Elliot, Heidi: 1 article (01/2022)
10.	Guo, Ruiting: 1 article (01/2022)

Related Diseases

1.	Thalassemia 01/01/2023 - "The United States Food and Drug Administration (FDA) approved betibeglogene autotemcel (beti-cel), the first cell-based gene therapy for adult and pediatric patients with b-thalassemia in August, 2022. " 01/01/2022 - "Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia." 06/07/2021 - "Objective: This study investigates the cost-effectiveness of betibeglogene autotemcel ('beti-cel'; LentiGlobin for β-thalassemia) one-time, gene addition therapy compared to lifelong SoC for TDT. " 06/07/2021 - "Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia." 01/01/2022 - "Betibeglogene autotemcel (beti-cel) gene therapy for transfusion-dependent β-thalassemia contains autologous CD34+ hematopoietic stem cells and progenitor cells transduced with the BB305 lentiviral vector encoding the β-globin (βA-T87Q) gene. "
2.	beta-Thalassemia (Cooley's Anemia) 11/01/2022 - "The effectiveness and value of betibeglogene autotemcel for the management of transfusion-dependent beta-thalassemia." 01/01/2020 - "Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia."
3.	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 08/01/2023 - "Similar retroviral and lentiviral technology can be applied to autologous haematopoietic stem cells, exemplified by Strimvelis and Zynteglo, licenced treatments for adenosine deaminase-severe combined immunodeficiency (ADA-SCID) and β-thalassaemia respectively. "
4.	Severe combined immunodeficiency due to adenosine deaminase deficiency 08/01/2023 - "Similar retroviral and lentiviral technology can be applied to autologous haematopoietic stem cells, exemplified by Strimvelis and Zynteglo, licenced treatments for adenosine deaminase-severe combined immunodeficiency (ADA-SCID) and β-thalassaemia respectively. "

Related Drugs and Biologics

1.	Globins
2.	betibeglogene autotemcel
3.	Activins (Activin)
4.	Ligands
5.	Adenosine Deaminase
6.	luspatercept

Related Therapies and Procedures

1.	Therapeutics
2.	Investigational Therapies (Experimental Therapy)